从“无差别轰炸”到“精准HER2，有靶打靶”：看懂关键区别

*文中图片均已获版权方授权，如需转载，请注明来源。

参考文献:

1.Yoon J, Oh DY. HER2-targeted therapies beyond breast cancer - an update. Nat Rev Clin Oncol. 2024 Sep;21(9):675-700. doi: 10.1038/s41571-024-00924-9. Epub 2024 Jul 22. PMID: 39039196.

2.Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021 Jan 28;14(1):20. doi: 10.1186/s13045-021-01035-z. PMID: 33509252; PMCID: PMC7844898.

3. taudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017 Dec 5;117(12):1736-1742. doi: 10.1038/bjc.2017.367. Epub 2017 Oct 24. PMID: 29065110; PMCID: PMC5729478.

4.Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA, Allison KH. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023 Aug 1;41(22):3867-3872. doi: 10.1200/JCO.22.02864. Epub 2023 Jun 7. PMID: 37284804.